INTRODUCTION

T helper 2 (T H 2) cells are effector T cells that differentiate from naïve CD4
+ T cells to produce the cytokines interleukin-4 (IL-4), IL-5, and IL-13. They enable protection against extracellular parasites but also promote allergic inflammation (1) . IL-4 is not only produced by T H 2 cells but also required for their differentiation in vitro and in vivo (2) . IL-4 signaling results in the activation of the transcription factor signal transducer and activator of transcription 6 (STAT6), which, in turn, induces the expression of GATA3, which encodes a key T H 2 cell-specific transcription factor. STAT6 and GATA3 (GATA binding protein 3) bind to regulatory regions of the T H 2 cytokine locus and activate expression of the IL4, IL5, and IL13 genes. Although IL-4 is produced by activated CD4 + T cells that are differentiating into T H 2 cells, the source of IL-4 in vivo during the initial stages of T cell activation remains unresolved. Several studies have identified additional cytokines that promote T H 2 cell responses in vivo (1, (3) (4) (5) . One of these is thymic stromal lymphopoietin (TSLP), which is produced by epithelial cells upon injury, dysfunction, or infection. Furthermore, TSLP is also produced by dendritic cells (DCs) and, thereby, could function during T cell priming in lymph nodes (6, 7) .
TSLP is strongly implicated in the pathogenesis of T H 2 cell-mediated allergic disorders, including atopic dermatitis, allergic asthma, food allergy, and eosinophilic esophagitis (8) . Some studies have reported that TSLP primarily acts on DCs to promote pathogenic T H 2 responses (9, 10) . However, others have implicated a role for TSLP signaling in CD4 + T cells in T H 2 cell-mediated inflammation (11) (12) (13) (14) . In this regard, ovalbumin (OVA)-sensitized, TSLP receptor (TSL-PR)-deficient (Crlf2 −/− ) mice fail to develop an inflammatory T H 2 cell response in their lungs to inhaled antigen (15) . However, transfer of wild-type (WT) CD4 + T cells that express the TSLPR into OVAsensitized Crlf2 −/− mice promotes allergic inflammation. Similarly, injection of WT CD4 + T cells into Crlf2 −/− mice also results in the development of allergic inflammation in the gut to OVA administration (16) . Thus, TSLP signaling in CD4 + T cells is required for the generation of robust pathogenic T H 2 responses in vivo. However, these analyses have not uncovered a direct role for TSLP in the differentiation of pathogenic T H 2 cells.
TSLP signals in mouse and human CD4 + T cells to induce the activation of the transcriptional regulator STAT5 through a pathway requiring the kinases Janus kinase 1 (JAK1) and JAK2 (11, 14) . TSLP increases the survival of naïve CD4 + T cells and that of memory T H 2 cells; the latter are a form of quiescent T H 2 cells that can be rapidly reactivated upon exposure to cognate antigens (17) . TSLP induces the secretion of IL-4 and IL-9 in conjunction with T cell receptor (TCR) activation (12, 13, 18) . In turn, IL-4 increases the expression of the TSLPR on CD4 + T cells, suggesting a positive feedback loop between the two cytokines (19) . We explored whether TSLP could directly promote the differentiation of naïve CD4 + T cells into T H 2 cells, particularly a "pathogenic" effector state that produces large amounts of IL-5 and IL-13. Furthermore, we analyzed the interplay between TSLP signaling and IL-4 signaling in the initiation and amplification of the T H 2 cell differentiation response and its culmination into a pathogenic state. Finally, we assessed the response of human CD4 + T cells to TSLP signaling and whether such potentially pathogenic T H 2 cell responses were enhanced in the context of asthma.
RESULTS
TSLP directly promotes T H 2 cell differentiation
To test the role of TSLP signaling in promoting T H 2 cell differentiation, we activated naïve CD4 + T cells in vitro with antibodies stimulating CD3 and CD28 and neutralizing interferon- (IFN-) in the presence of IL-4, TSLP, or both for 3 days. Compared with IL-4-induced T H 2 cell differentiation, TSLP statistically significantly increased the frequency of T H 2 cells producing IL-4, IL-5, and IL-13 ( Fig. 1, A and B) and increased the amount of IL-5 and IL-13 produced per cell (fig. S1A). Increase in both the frequency and amplitude of production resulted in increased secretion of IL-4, IL-5, and IL-13 ( fig. S1 , B and C). Notably, the addition of exogenous IL-4 during TSLP stimulation did not augment T H 2 cytokine production ( Fig. 1, A S1F ), which is an essential transcription factor for T cell activation and T H 2 cell differentiation (20, 21) . Consistent with a previous report (14) , TSLP reduced the apoptosis of naïve CD4 + T cells ( fig. S1D ). These results suggest that TSLP signaling increases the frequency of T H 2 cells that produce IL-4, IL-5, and IL-13 through mechanisms that do not involve altered IRF4 activation or enhanced survival or proliferation of activated cells.
TSLP signaling is mediated by a receptor complex containing IL-7 receptor  (IL-7R) and TSLPR (22) . Given the shared IL-7R subunit between TSLPR and IL-7R, we tested the effect of IL-7 on T H 2 cell differentiation in relation to TSLP. Although IL-7 also stimulated the production of IL-13-positive cells that were indicative of T H 2 cell differentiation, IL-7 was less effective than TSLP (Fig. 1, A and B) despite inducing greater STAT5 activation under the culture conditions ( Fig. 1, C and D) . These results suggest that TSLP may use one or more additional signaling pathways in conjunction with the JAK-STAT5 pathway to efficiently drive T H 2 cell differentiation.
TSLP initiates T H 2 cell programming in the absence of IL-4
Although TSLP signaling induced an increase in the abundance of IL-4 ( fig. S1B ) and IL-4R ( fig. S2A) , which promote T H 2 cell differentiation (12) , the observation that TSLP increased the frequency of IL-5-and IL-13-positive cells to a greater extent than did IL-4 alone suggested that TSLP could function independently of or in synergy with IL-4. To test the action of TSLP in the absence of IL-4 signaling, we included function-blocking antibodies to IL-4 and IL-4R during CD4 + T cell differentiation. Even in the presence of the function-blocking antibodies, TSLP stimulated the induction of Il4, Il5, and Il13 expression within 24 hours of CD4 + T cell activation ( Fig. 2A) . However, expression of these T H 2 cytokine genes was not amplified at the later time points in the absence of IL-4. This correlated with the lack of induction of Gata3 expression by TSLP in the absence of IL-4 signaling, which is consistent with a dependence of Gata3 expression on the IL-4/STAT6 pathway. As expected, the function-blocking antibodies abolished IL-5 and IL-13 secretion during IL-4-induced T H 2 cell differentiation (Fig. 2B) , indicating that this was an effective method for blocking IL-4 signaling. Consistent with the gene expression data ( Fig. 2A) , TSLP, in the presence of the IL-4-and IL-4R (IL-4/IL-4R)-blocking antibodies, induced IL-5 and IL-13 secretion but at substantially reduced amounts (Fig. 2B) .
To complement the antibody-mediated blockade of IL-4 signaling, we performed similar experiments with Il4 −/− CD4 + T cells. As we observed with the IL-4/IL-4R-blocking antibodies, activation of Il4 −/− CD4 + T cells with TSLP induced production of both IL-5 and IL-13, albeit at reduced amounts than in the presence of exogenously added IL-4 ( (Fig. 3B) . These results show that T H 2 TSLP cells preferentially express a small module of allergy-promoting and proinflammatory cytokine genes and this likely enables their enhanced effector functions.
Of the repressed genes, Bcl6 was the most differentially affected in T H 2 TSLP cells, and this was confirmed by real-time PCR analysis (Fig. 3C) , which resulted in reduced protein abundance, as analyzed by flow cytometry (Fig. 3D and fig. S3B ). To test whether the repression of Bcl6 expression by TSLP signaling was required for T H 2 cell differentiation, we transduced activated CD4 + T cells with a retroviral vector encoding Bcl6. Enforced expression of BCL6 in activated CD4 + T cells abolished the TSLP-induced expression of T H 2 cytokine genes (Fig. 3E) . Our results are consistent with the finding that BCL6 directly represses the Il13 gene in the context of T follicular helper cell differentiation (23) . We therefore propose that the antagonism of Bcl6 induction by TSLP (Fig. 3D) promotes the increased frequency and cytokine output of IL-13-producing T H 2 TSLP cells.
TSLP induces T H 2 cytokine expression through JAK2 and STAT5
To determine whether the JAK-STAT5 pathway activated by TSLP (14) , in the absence of IL-4 signaling, was required for the induction of T H 2 cytokine gene expression, we performed experiments with Il4 −/− CD4 + T cells and a JAK2-selective inhibitor (14, 24) . We confirmed that JAK2 inhibitor II blocked the phosphorylation of STAT5 induced by TSLP (Fig. 4A) but not the phosphorylation of STAT6 induced by IL-4 ( fig. S4A ) nor the phosphorylation of STAT5 induced by IL-7 (fig. S4B) ; signaling by the latter cytokines is dependent on the kinases JAK1 and JAK3 (25) . Furthermore, the induction of the Il5 and Il13 genes by TSLP was abrogated by the JAK2 inhibitor (Fig. 4B) . As expected, the induction of Gata3 expression by IL-4 signaling was unaffected under these conditions of JAK2 inhibition (Fig. 4B) . Surprisingly, the repression of BCL6 by TSLP signaling was not affected by the inhibition of the JAK2-STAT5 pathway ( fig.  S4C ). To validate these results, we used retroviral Cre-mediated deletion of the Stat5a and Stat5b genes in preactivated and rested CD4 + T cells isolated from Stat5a/5b fl/fl mice. In the absence of STAT5 ( fig. S4D ), TSLP signaling was unable to induce expression of T H 2 cytokine genes (Fig. 4C) . Note that TSLP still inhibited BLC6 accumulation in the absence of STAT5A/STAT5B (Fig. 4D) . We note that, in CD4 + T cells, which were activated and then rested to enable retroviral transduction ("preactivated"), loss of STAT5A/STAT5B resulted in a modest increase in BCL6 abundance. Nevertheless, experiments involving the chemical inhibition of JAK2, when coupled with deletion of the Stat5a/Stat5b locus and constitutive expression of Bcl6, provide evidence that there are distinct pathways by which TSLP signaling promotes robust T H 2 cell differentiation.
TSLP enhances activating chromatin modifications at T H 2 cytokine loci
We next analyzed the chromatin states of T H 2 TSLP versus T H 2 IL-4 cells by performing chromatin immunoprecipitation sequencing (ChIP-seq) analysis for the activating histone modification, H3K27ac. Consistent antibodies against CD3, CD28, and IFN- for 1 day and then were transduced with retroviruses expressing green fluorescent protein (GFP) or Bcl6-GFP. After an additional 2 days of activation and 1 day of rest in culture medium, the cells were sorted for GFP expression and then reactivated with antibodies against CD3 and CD28 in the presence or absence of TSLP. RNA was isolated after 14 hours and analyzed for Il4, Il5, and Il13 transcripts by qPCR. Data are means ± SEM of four experiments.
Where statistics are indicated, data were analyzed by two-way ANOVA. *P ≤ 0.05, **P ≤ 0.01, and ***P ≤ 0.001. Data are means ± SEM of three experiments and were analyzed by two-way ANOVA. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, and ****P ≤ 0.0001.
with our RNA-seq analysis, most H3K27ac regions that were induced preferentially under T H 2-polarizing conditions (2611 peaks) were shared in T H 2  IL-4 and T H 2  TSLP cells (fig. S5A and table S5 ). However, there were a small number of H3K27ac regions (90 peaks) that were more highly acetylated in the presence of TSLP. Furthermore, seven of these hyperacetylated chromatin regions occurred within the T H 2 cytokine locus that encodes Il4, Il5, and Il13 (Fig. 5A and table S5 ). Analysis of H3K4me3 by ChIP-seq demonstrated that the hyperacetylated regions around the Il13 locus were associated with increased H3K4me3 in the presence of TSLP (Fig. 5A) . Similar patterns of activating histone modifications, which were dependent on TSLP signaling, were observed near the Il24 gene (Fig. 5B) , which encodes an additional T H 2-type cytokine (26, 27) . As anticipated by the analysis of activating histone modifications, the Il24 gene was more highly expressed in T H 2 TSLP cells than in T H 2 IL-4 cells ( fig. S5B ). Furthermore, STAT5 activated by TSLP bound to regulatory regions within the T H 2 cytokine and Faim/Il24 loci, which displayed enhanced H3K27ac and H3K4me3 in T H 2 TSLP cells (Fig. 5, A and B). Given that T H 2 TSLP cells depend on an interplay between exogenous TSLP and endogenous IL-4 that is expressed during their differentiation, we examined whether TSLP signaling could induce H3K27ac in the absence of IL-4 at the early time point, when TSLP-mediated expression of T H 2 cytokines was observed ( S5D ) and that this transcriptional programming was not associated with increased H3K27ac, our results suggest a mechanism for TSLP-activated gene expression that is independent of this histone modification. This mechanism may also function to enhance IL-4-mediated gene activation that is associated with increased H3K27ac.
The TSLP-primed effector state is stably programmed in memory T H 2 cells
To determine whether the robust TSLP-primed effector state was stably programmed in memory T H 2 cells, we used an adoptive transfer approach (28, 29) . Naïve CD45.1 + CD4 + T cells were differentiated into T H 2 IL-4 or T H 2 TSLP cells (Fig. 1A) , and equal numbers were transferred into CD45.2 + recipient mice (Fig. 6A) . T H 0 cells were used as controls. The frequency and phenotype of the donor cells (CD45.1
were assessed 34 days after transfer. T H 2 IL-4 or T H 2 TSLP cells were recovered in equivalent numbers that were more abundant than their T H 0 counterparts (Fig. 6B) . Consistent with their memory phenotype, a large fraction of the T H 2 and T H 2 TSLP cells displayed cell surface expression of CD44 and IL-7R (CD127) (Fig. 6C) . Consistent with their memory T H 2 cell state, the T H 2 IL-4 and T H 2 TSLP cells rapidly increased the abundance of the transcription factors GATA3 and IRF4 after stimulation with antibodies against CD3 and CD28 compared with T H 0 cells and naïve cells (Fig. 6D) . Furthermore, they gave rise to an increased frequency of cells producing IL-4, IL-5, or IL-13 ( (Fig. 6F) . These results suggest that TSLP signaling during a primary CD4 + T cell response can stably program a greater effector cytokine output in memory T H 2 cells, which is manifested after secondary activation simply by engagement of the TCR and its co-receptor CD28. Such molecular programming may involve an alteration of chromatin structure that predisposes for increased H3K27 acetylation at the Il5 and Il13 genes upon secondary activation.
TSLP signaling in T cells provokes a hyperinflammatory T H 2 response
To test the role of TSLP signaling in CD4 + T cells in enhancing a pathogenic T H 2 cell response, we used the house dust mite (HDM) model of allergic airway inflammation that is widely used for the study of allergic asthma (30) . Tcra −/− mice, which lack endogenous T cells, were reconstituted with WT or TSLPR-deficient (Crlf2
+ T cells (31) . One month later, the mice were sensitized with HDM by intratracheal administration (Fig. 7A ). This experimental design enabled us to specifically examine the effects of perturbing TSLP signaling in CD4 + T cells while retaining TSLP responsiveness in other immune cells. Analysis of CD4 + T cells in the blood of control and test mice showed comparable numbers of donor cells (Fig. 7B) . Upon HDM administration, there was an equivalent increase in the numbers of donor CD4 + T cells in the lungs of both groups of mice. Compared to HDM-exposed mice reconstituted with WT CD4 + T cells, similarly exposed mice reconstituted with Crlf2 −/− CD4 + T cells manifested a weaker T H 2 inflammatory response, which was characterized by reduced amounts of IL-4, IL-5, and IL-13 ( Fig. 7C ) and diminished numbers of eosinophils and macrophages in the bronchoalveolar lavage (BAL) fluid (Fig. 7D) . Note that the secretion of IFN- and IL-17A was not affected (fig. S6A ). Consistent with these findings, mice transplanted with Crlf2 −/− CD4 + T cells manifested reduced bronchial hyper-reactivity to challenge with methacholine (Fig. 7E) S6D ). These results, coupled with our in vitro analyses, suggest that TSLP signaling in CD4 + T cells specifically enhances their ability to undergo robust differentiation into T H 2 cells, resulting in the increased production of IL-5 and IL-13.
TSLP functions together with IL-4 to induce the expression of T H 2 cytokines by human CD4 + T cells To assess the effect of TSLP on human CD4
+ T cells, such cells were purified from healthy or asthmatic donors and activated in the presence of IL-4, TSLP, or both cytokines (Fig. 8A) . Although TSLP and IL-4 alone had modest effects on the expression of T H 2 cytokine genes, in combination, they induced robust increases in the expression of IL4, IL5, and IL13 (Fig. 8B) , as well as secretion of IL-5 protein (Fig. 8C) . Note that, in asthmatic donors, there was more pronounced expression of T H 2 cytokine genes and IL-5 protein. These results suggest that human CD4 + T cells also display a dual requirement for TSLP and IL-4 to enable their robust differentiation into T H 2 cells. Furthermore, such T H 2 cell responses were enhanced in the peripheral T cell compartment of asthmatic children. 
DISCUSSION
To gain insight into the interplay of TSLP and IL-4 in the generation of T H 2 cells, we used an in vitro system in which each signaling pathway could be independently manipulated. Our results suggest that TSLP initiates T H 2 cell programming, involving induction of the expression of the genes encoding IL-4, IL-5, and IL-13, in the absence of IL-4 signaling. However, this transcriptional response was not sustained or amplified in the absence of IL-4 signaling. We note that T cells activated in the presence of TSLP induced the production of IL-4 and increased the abundance of IL-4R to establish a feed-forward loop for robust T H 2 cell differentiation that did not require exogenously supplied IL-4. Nonetheless, TSLP signaling promoted T H 2 cell differentiation by pathways that extend beyond the induction of the IL-4 feed-forward loop. This is because, during T H 2 cell differentiation, TSLP specifically increased the frequency of IL-4-, IL-5-. and IL-13-expressing effector cells that had enhanced cytokine production. This was not observed when T cells underwent T H 2 cell differentiation simply in the presence of saturating amounts of exogenous IL-4. A similar effect of TSLP and IL-4 signaling was observed in human CD4 + T cells. In the human context, IL-4 or TSLP signaling induced the production of low amounts of T H 2 cytokines, and the combination of IL-4 and TSLP was necessary for robust T H 2 cell differentiation. Thus, we propose a dual cytokine model for robust T H 2 cell differentiation, involving an interplay of TSLP and IL-4 signaling that is analogous to the interplay among IL-6, IL-21, and IL-23 in the context of T H 17 cell differentiation (32, 33) and that of IL-27 and IL-12 in the context of T H 1 cell differentiation (34) .
IL-2 and STAT5 are essential for T H 2 cell differentiation, both for initiating chromatin accessibility at the Il4 locus and for increasing expression of the Il4ra gene, thereby priming cells for T H 2 cell differentiation (5, (35) (36) (37) . Our current results provide insights into the role of STAT5, suggesting that activation of the STAT5 pathway by TSLP, followed by IL-4 activation of the STAT6-GATA3 pathway, is required for the robust amplification of T H 2 cytokine gene expression and enhanced T H 2 cell differentiation. Surprisingly, IL-7, whose receptor shares the IL-7R chain with TSLPR, induced stronger activation of STAT5 than did TSLP but was less effective in promoting T H 2 cell differentiation. A key finding is that TSLP signaling inhibited the induction of Bcl6 expression during T cell activation in a JAK2-and STAT5-independent manner. BCL6 directly represses Il4, Il9, and Il13 expression in CD4 + T cells; thus, its loss leads to increased production of T H 2 cytokines (23, 38, 39) . Here, we showed that, by antagonizing the induction of BCL6, TSLP promoted the generation of IL-13-expressing cells and magnitude of Il13 gene expression through a STAT5-independent manner. Hence, we propose that TSLP promotes T H 2 cell differentiation through two distinct molecular pathways: the activation of STAT5 by JAK2 and the repression of Bcl6 expression, which is not mediated by STAT5. The two pathways appear to function synergistically because STAT5 activation in the presence of sustained Bcl6 expression did not enable induction of T H 2 cytokine gene expression. Conversely, the TSLP-mediated repression of Bcl6 expression in the absence of STAT5A and STAT5B was not sufficient to activate the expression of Il5 and Il13.
The genomic consequences of TSLP signaling in the first 24 hours of CD4 + T cell activation are highly focused and include the hallmark T H 2 cytokine loci, Il4, Il5, and Il13. Furthermore, this initial transcriptional programming is dependent on the JAK2-STAT5 pathway and can occur in the absence of IL-4 signaling. Note that STAT5 binds to regulatory regions associated with the Il4, Il13, and Il9 genes (39) . Thus, we propose that the initial programming of the T H 2 cell effector state by TSLP signaling involves focal binding and activation by STAT5. This proposal is consistent with the demonstration that expression of a constitutively activated STAT5 protein in naïve CD4 + T cells, primed in the absence of IL-2 signaling, promotes T H 2 cell differentiation even under conditions of IL-4 signaling blockade (35) . Note that, under conditions of TSLP signaling, the initial activation of expression of the T H 2 cytokine loci by STAT5 was not accompanied by an increase in the activating histone modification H3K27ac at associated regulatory regions. In contrast, the combined The control group contained four children (8 to 9 years of age) and two adults, whereas the asthmatic group contained eight children (5 to 11 years of age). Data were analyzed by one-way ANOVA. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, and ****P ≤ 0.0001.
action of TSLP and IL-4 signaling at later stages of T H 2 cell differentiation resulted in an increase in H3K27ac and H3K4me3 at regulatory regions of the T H 2 cytokine loci. These robust histone modifications were not observed with IL-4 alone and were associated with the increased frequency of IL-4-, IL-5-, and IL-13-expressing effector cells with enhanced cytokine production. Thus, underlying our dual cytokine model for robust T H 2 cell differentiation is the sequential and synergistic action of TSLP-activated STAT5 and IL-4-activated STAT6, the latter of which results in the induction of the gene encoding the T H 2 cell transcription factor GATA3. Consistent with this regulatory model, expression of a constitutively activated STAT5 protein, together with GATA3, in activated CD4 + T cells induces more robust T H 2 cell differentiation than does either STAT5 or GATA3 alone (35) . The most striking consequence of TSLP signaling in activated CD4 + T cells is that it programs a robust T H 2 effector potential in memory cells. Although this TSLP-primed memory T H 2 state was not associated with increased H3K27 acetylation at regulatory regions of T H 2 cytokine loci, it resulted in enhanced H3K27 acetylation and cytokine gene expression upon secondary activation. The nature of the epigenetic alterations induced by transient TSLP priming that are stably propagated in memory T H 2 cells remains to be explored.
Although it is known that TSLP plays a critical role in allergic disorders and asthma through stimulating DCs (3, 9, 40, 41) , its direct action on T cells and T H 2 cell responses in vivo has been underappreciated. A few studies previously investigated a direct effect of TSLP on effector and memory CD4 + T cells in the context of OVA models of allergic diseases (15) (16) (17) 42) . Here, using the HDM model of airway inflammation, which has pathophysiological features similar to those of human allergic asthma, we demonstrated that CD4 + T cells that responded to TSLP generated more pronounced asthma symptoms. Our in vivo findings highlight the importance of TSLP signaling through its direct actions in promoting robust T H 2 cell differentiation. Our results are consistent with findings that CD4 + T cells that cannot respond to TSLP and IL-33 are impaired in their potential to produce IL-5 and IL-13 in the context of Nippostrongylus brasiliensis infection (43) .
Distinct T H 2 cell subsets are generated during allergic responses (18, (44) (45) (46) . Some of these cells produce large amounts of IL-5, IL-9, and IL-13. These cells have been termed pathogenic T H 2 cells. We note that TSLP-primed T H 2 cells (T H 2 TSLP ) have characteristics of pathogenic T H 2 cells because they produce large amounts of IL-5, IL-9, and IL-13. Furthermore, several genes that are notable in pathogenic T H 17 cells were also strongly expressed in T H 2 TSLP cells, such as Ccl3, Ccl4, Il3, and Csf2. Consistent with this similarity, TSLP increased activating histone modifications in the Faim3-Il24 locus; Faim3 is implicated in the pathogenicity of T H 17 cells (33) , and IL-24 is suggested to be an additional T H 2-type cytokine (27) . These observations suggest that pathogenic T H 2 cells generated by TSLP priming share some features with their T H 17 cell counterparts. We propose that the severity of allergic responses and asthma may be determined by the proportion of conventional T H 2 and pathogenic memory T H 2 cells, the latter generated by TSLP priming. Furthermore, although memory T H 2 TSLP cells displayed characteristics shared with IL-4-primed memory T H 2 cells, such as the rapid increased production of GATA3 and IRF4, they manifested an increased capacity to produce IL-5 and IL-13 after restimulation in the absence of TSLP (Fig. 6) . Together, our findings suggest that TSLP signaling in naïve CD4 + T cells in conjunction with IL-4 signaling increases the pathogenicity of T H 2 effector and memory cells. Asthmatic children exhibited more pronounced T H 2 cell responses in their peripheral T cell compartment in response to TSLP and IL-4 signaling. It remains to be determined whether this is due to an increase in the number of pathogenic memory T H 2 cells. Thus, the blockade of TSLP signaling during the priming of allergic T H 2 responses in childhood may prove beneficial in preventing the progression of allergic disorders to severe asthma.
MATERIALS AND METHODS
Study design
The aim of this study was to elucidate the actions and molecular mechanisms by which TSLP induces the differentiation of pathogenic T H , and Il4 −/− mice were purchased from The Jackson Laboratory. Crlf2 −/− mice were described previously (47) . These strains were on a C57BL/6 background. Stat5a/5b fl/fl mice have been described previously (48) and were back-crossed for multiple generations to BALB/c mice. Both female and male mice (6 to 12 weeks of age) were used for in vivo and in vitro studies. Mice were housed under specific pathogen-free conditions. All experiments complied with protocols approved by the Cincinnati Children's Hospital Medical Center (CCHMC) Animal Use and Care Committee. − naïve cells. Purified naïve CD4 + T cells (95 to 98% purity) were activated with plate-bound anti-CD3 (5 g/ml), soluble anti-CD28 (2 g/ml), and soluble anti-IFN- (10 g/ml). Each of these antibodies was obtained from BioXCell. T cells were additionally stimulated with TSLP (40 ng/ml; R&D Systems), IL-4 (20 ng/ml; PeproTech), or IL-7 (20 ng/ml; PeproTech). Cells were cultured in RPMI 1640 (Thermo Fisher Scientific) containing 10% fetal bovine serum (FBS), l-glutamine, -mercapethanol, and antibiotics. To neutralize IL-4, anti-IL-4 (10 g/ml; 11B11, BioXCell) and anti-IL-4R (5 g/ml; BD Biosciences) were added. The amounts of IL-4, IL-5, and IL-13 secreted by cells into the culture medium were analyzed by enzyme-linked immunosorbent assay (ELISA) with specific kits from R&D Systems. To inhibit JAK2 activation, CD4 + T cells were preincubated for 1 hour with 50 M JAK2 inhibitor II (CAS 1837-91-8, Calbiochem/ Sigma-Aldrich) and then activated for the times indicated in the figure legends in the presence of JAK2 inhibitor II. Dimethyl sulfoxide was used as a control. Human peripheral blood mononuclear cells were isolated by Ficoll gradient centrifugation and then purified with CD4 + T Cell Isolation kits (Miltenyi Biotec) from the whole blood of healthy or asthmatic donors. Purified cells (98% purity) were activated with soluble anti-CD3 (5 g/ml), anti-CD28 (2 g/ml; BioXCell), and anti-IFN- (5 g/ml; BioLegend) in the presence or absence of TSLP (40 ng/ml), IL-4 (40 ng/ml), or both. fl/fl CD4 T cells, respectively. Transduced cells were incubated under activation conditions for an additional 2 days, rested for 24 hours, and then fluorescence-activated cell-sorted on the basis of green fluorescent protein (GFP) expression. GFP + cells were reactivated with anti-CD3 (2 g/ml; plate-bound) and anti-CD28 (2 g/ml; soluble) antibodies with or without TSLP (40 ng/ml). BCL6 protein was detected by intracellular staining 5 hours after activation. RNA was isolated and analyzed 14 hours after activation. + T cells were washed in phosphate-buffered saline (PBS), resuspended in 100 l of annexin V buffer, and stained with FITC-annexin V and 7-amino-actinomycin D (BD Biosciences) for 15 min at room temperature before being analyzed by flow cytometry.
T cell isolation and stimulation
Retroviral transduction of cells to express
Flow cytometry analysis
Proliferation assays
Purified naïve CD4 + T cells were labeled for 8 min at room temperature with 2.5 M carboxyfluorescein diacetate succinimidyl ester (Molecular Probes) and then activated with various concentrations of anti-CD3 antibody in the presence of anti-CD28 and anti-IFN- antibodies with or without TSLP for 3 days. + T cells. One month later, the mice were anesthetized with ketamine/xylazine, which was followed by intratracheal administration of either 40 l of PBS or 100 g of HDM in 40 l of PBS (Greer Laboratories). HDM was administered two additional times at 1-week intervals. Two days after the last challenge, the mice were sacrificed by pentobarbital injection, and the organs were dissected for analysis. BAL fluid was collected with 1 ml of PBS by cannulation of the trachea and centrifuged at 500g for 5 min. The supernatant was used for the measurement of cytokines by ELISA. The cell pellet was resuspended in PBS containing 2% FBS and centrifuged in a Cytospin at 500g for 5 min. Slides were stained with KWIK-DIFF Stain kit (Thermo Fisher Scientific) to enable morphology-based cell counts. At least 200 cells in random fields were counted for each sample. Lung function analysis was performed using a flexiVent invasive measurement of dynamic resistance, as described previously (49) .
Adoptive transfer and generation of T H 2 cells in vivo
RNA isolation and analyses
Naïve CD4
+ T cells were activated with antibodies against CD3, CD28, and IFN- in the presence or absence of TSLP or IL-4 for 0, 2, 6, 24, 48, and 72 hours. RNA was isolated using the Aurum Total RNA kit (Bio-Rad). For real-time PCR analysis, RNA was reverse-transcribed with the iScript cDNA Synthesis kit (Bio-Rad). All primers and probes were purchased from Integrated DNA Technologies (IDT) (table S6). The ABI 7900HT Fast Sequence Detection System was used to quantitate PCR products. The abundances of the transcripts of interest were determined relative to that of Eif3k complementary DNA (cDNA). For RNA-seq analysis, mRNA was purified from total RNA with the Dynabeads mRNA Purification kit (Invitrogen) and reverse-transcribed with the SuperScript Double-Stranded cDNA Synthesis kit (Invitrogen). The deoxyuridine triphosphate (dUTP) method was used for the preparation of RNA-seq libraries. Next-generation RNA-seq was performed by the CCHMC DNA Sequencing and Genotyping Core with Illumina TruSeq kits and an Illumina HiSeq 2000 sequencing system, which resulted in ~20 million paired-end reads per sample. RNA-seq data are available from the Gene Expression Omnibus (GEO) database (accession number: GSE81384). RNA-seq data analysis was performed with BioWardrobe (50) . Briefly, reads were mapped with RNA-STAR 23104886, and reads per kilobase of transcript, per million mapped reads (RPKM) calculations were performed with the BioWardrobe algorithm. Differential gene expression analysis was performed with DESeq2 (51) . Genes were considered to be differentially expressed if P adj ≤ 0.05 for at least one time point. Two additional cutoffs were used: a change in expression of more than twofold (higher or lower) and an RPKM value of ≥5 in at least one sample. Biological processes and pathway analyses for gene clusters were assigned with ToppGene software (52) .
Chromatin immunoprecipitation sequencing
Cells were cross-linked with 1% formaldehyde for 8 min, and chromatin was prepared as previously described (53) . Sonication was performed with a Covaris S220 focused ultrasonicator (Covaris Inc.) at 175-W peak incident power, 10% output, and 200 bursts for 5 min. DNA fragmentation was verified by agarose gel electrophoresis. ChIP was performed with a rabbit polyclonal anti-H3K27ac antibody (Diagenode Inc.), a rabbit monoclonal anti-H3K4me3 antibody (17-614, Millipore), or a rabbit polyclonal anti-STAT5A/5B antibody (AF1584, R&D Systems) and Dynabeads Protein G (Invitrogen) in radioimmunoprecipitation assay buffer (10 mM tris-EDTA, 0.1% SDS, 1% Triton X-100, 150 mM NaCl, and 0.1% sodium deoxycholate). ChIP DNA was converted into indexed libraries with the ThruPLEX DNA-seq kit (Rubicon) and was sequenced on an Illumina HiSeq 2000 sequencing system, which resulted in ~20 to 40 million single-end reads per sample. Data analysis was performed in BioWardrobe (50) . Briefly, reads were mapped with BowTie and displayed on a local mirror of the UCSC genome browser as coverage by estimated fragments. Peaks were identified by MACS2, and differential enrichment was analyzed with MAnorm. ChIP-seq data are available from the GEO database (accession number: GSE81384). For ChIP-PCR, IDT primers and probes labeled with fluorescein amidite were used (table S7).
Statistical analyses
All statistical analyses were performed with Prism 6 software (GraphPad Software Inc.), as described in the figure legends: *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, and ****P ≤ 0.0001.
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